Drug discovery’s latest top-level appointments


The last couple of months has seen a number of changes in senior roles in the drug discovery sector.

Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma, pharmaceutical and clinical research (CRO) industries.

Dr Uwe Gottschalk, Chairman of the Board of Directors, Cellevate: Dr Gottschalk currently serves as an Operating Partner at Keensight Capital. He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021.

Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen. Hall has been with the company for more than 16 years, including as Chief Commercial Officer, and was previously Head of Business Development in Europe for Cyprotex. Bironneau brings over two decades of commercial leadership experience, including as Vice President, Global Sales & Business Development at Axplora and Novasep.

Rachael Thomas Higgins, Chief Commercial Officer, PicnicHealth: Higgins previously served as Vice President of Commercial Sales at CorEvitas through its acquisition by Thermo Fisher Scientific and has held leadership roles at Circuit Clinical, TriNetX, and Covance.

Rob Scott, Christian Hein, Michel Vounatsos, Advisory Board, QuantHealth: Scott was former Chief Medical Officer for AbbVie, Hein was former VP and Global Head of Digital Transformation & Innovation Execution at Novartis, and Vounatsos was former CEO of Biogen.

Scott Kobayashi, Senior Vice President of Sales, BioPhy: Kobayashi previously founded Delta Project Management, a life sciences consulting firm he sold to Versita in 2022, and held consulting roles with companies like Pfizer, Genentech, and Flour.

Dr Scott Braunstein and Dr Vincent Miller, Board of Directors, One Biosciences: Dr Braunstein is Chairman and CEO of Marinus Pharma and Operating Partner of Aisling Capital. Dr Miller has received the American Cancer Society Clinical Oncology Career Development Award. He previously served as Physician-in-Chief, EQRx and as Chief Medical Officer at Foundation Medicine.

Jean-Baptiste Agnus, Chief Business Officer, and Peter Carbone, Chief Quality Officer, KBI Biopharma: Agnus brings more than two decades of experience in the biopharmaceutical industry with expertise in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and cell and gene therapies. Carbone brings over 35 years of experience in operations, quality, and technology leadership in biotechnology, pharmaceuticals, and advanced therapies.

Scott Lassonde, SVP, Chief Financial Officer, Veranova: Lassonde has 14 years experience as a Chief Financial Officer in private equity-backed manufacturing-based businesses. Prior to joining Veranova, he served as CFO at Lacerta Group.

Catherine Miller Collis, Senior Vice President of Growth Strategy, Januar Health, and Massimo Radaelli, President, Jaguar International: Catherine Miller Collis moved from a role as Chief Commercial Officer at Vibrant Gastro. She previously worked at Vertex Pharmaceuticals as VP Global Marketing, and at Zealand Pharma as VP, US Sales and Marketing. Dr Radaelli has more than 35 years’ experience in biopharmaceuticals for rare diseases, a member of the board of directors of Napo Therapeutics and temporarily served as Napo Therapeutics’ Interim Executive Director.

Kim Ferguson, Vice President of Global Sales and Support, Scale Biosciences: Prior to joining ScaleBio, Ferguson served as Vice President of Global Sales Operations at DNA Script. Previously, she held roles at Illumina, Eppendorf, VWR International, Orthologic Corp, and Natick Soldier Center.

Dr Mutlu Dogruel, Vice President for AI Solutions, Cresset: Dr Dogruel joins from Microsoft, where he worked as Pharma GenAI Lead Architect and Senior Cloud Solution Architect in Data and AI. He has a PhD in Bioinformatics from the University of Cambridge.

Dr Anker Lundemose, Non-Executive Director, IsomAb: Lundemose, who qualified with a medical degree from Aarhus University in Denmark, is currently Chief Executive Officer of MISSION Therapeutics in Cambridge, UK.

Edward Rayner, Non-Executive Director, Sphere Fluidics: Rayner has held a number of key analyst and portfolio management positions at leading research-led investment firms, including AMP Capital, Alliance Bernstein, UBS Asset Management and JP Morgan Investment Management.

Shelly Adams, Chief Commercial Officer, Likarda: Adams joins from Erbi Biosystems, part of Millipore Sigma, where she served as Vice President of Sales. She has over 25 years of global sales and management experience, within the biotechnology, cell therapy, diagnostics, medical device and technical services industries.

Dr Sam Barrell CBE, Chief Executive Officer, LifeArc: Barrell joins from the Francis Crick Institute where she is currently Deputy CEO. She has held a number of senior leadership positions in the NHS, most recently as CEO of Taunton and Somerset NHS Foundation Trust.

Margrethe Sørgaard, Senior Vice President of Clinical Operations and Pharmacovigilance, Calluna Pharma: Sørgaard brings over 25 years’ experience from different leading positions in clinical development and operations, medical affairs, and drug safety/pharmacovigilance.

Dr Jim Faulkner, Dr Nicole Mather and Dr Carolyn Porter, Non-Executive Board Members, Cell and Gene Therapy Catapult: Dr Faulkner has previously held positions at Apple Tree Partners, Ascidian Therapeutics, Autolus Ltd and GlaxoSmithKline. Dr Mather currently leads IBM’s Health Data & AI and Life Sciences teams in the UK and Ireland. Dr Porter is currently CEO of Outrun Therapeutics and has previously worked for Novartis, Chiron, Oxford University and Ernst & Young.

Dr David Witty, Chief Scientific Officer, Sygnature Discovery: Dr Witty has held many senior leadership roles in the pharmaceutical and drug discovery industry, including Director of Chemistry and Head of Operations at Convergence Pharmaceuticals.

Bob Kain, Advisor, Single Technologies: Kain worked at Illumina from 1999 to 2014 where he helped invent and commercialise the first modern, high throughput genome sequencer. He is lead inventor on 28 US patents linked to genome sequencing.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free